The global Protein Expression Market is expected to reach USD 3.0 billion by the year 2025 growing at a CAGR of 10.4%, according to a new report by Grand View Research, Inc. The growing demand for biologics and expansion of the biopharmaceutical industry have resulted in massive growth of the protein expression market. Rising demand for therapeutic proteins such as insulin, hormones, monoclonal antibodies and vaccines is a major factor that propels growth of the market during forecast period. Thus, many biotechnology and pharmaceuticals companies have begun to concentrate on the development and manufacturing of advanced therapeutic proteins for the treatment of severe chronic diseases such as cancer, hemophilia, infectious diseases, anemia, and multiple sclerosis.
Increasing investment in the R&D, by biotechnology and pharmaceutical companies, is another major factor supporting the sector growth. The availability of new and advanced technologies to cater the needs of drugs & biologics product manufacturers boosts the adoption of protein expression products for research and manufacturing applications. In addition, several pharmaceutical and biotechnology manufacturers are undergoing collaborations and partnerships to achieve leadership in the sector. For instance, in December 2016, Takara Bio, Inc. signed a merger agreement with Rubicon Genomics, Inc. to strengthen its genomics business. Browse Details of Report @ http://www.grandviewresearch.com/industry-analysis/protein-expression-market Further Key Findings From The Report Suggest:
0 Comments
The global Molecular Biology Enzymes, Reagents And Kits Market size is expected to reach USD 29.3 billion by 2027, expanding at a CAGR of 11.0%, according to a new report by Grand View Research, Inc. The molecular biology field holds great potential to advance the medical treatments based on increasing scientific knowledge of cellular processes coupled with improving access to proteomics and genomics data. Personal genome sequencing is also expected to gain traction in the development of tailored diagnostics for each patient. A confluence of these factors drives the demand for molecular biology enzymes, reagents, and kits in the expansion of advanced personalized treatments.
Market players are engaged in constant product launches to enhance the efficiency of existing techniques and generate molecular information more easily, rapidly, and accurately. For instance, in June 2020, PCR Biosystems introduced a 4x RT-qPCR kit, qPCRBIO Probe 1-Step Virus Detect, designed for high-throughput, ultra-sensitive detection of viral RNA sequences, such as coronavirus. This new kit is proven to offer successful research in diagnostic projects. Besides, synthetic biology is a rapidly advancing biotechnology field, which applies robust, innovative methods for drug manufacturing, cell therapies, and clinical diagnostics. Funding initiatives in this field expand its applications, which boost the usage of molecular biology products in these applications. As per SynBioBeta data, 37 synthetic biology companies raised USD 1.2 billion in the second quarter and 65 synthetic biology firms received USD 1.9 million funding in the first quarter of 2019. Request a free sample copy or view report summary: Molecular Biology Enzymes, Reagents And Kits Market Report Molecular Biology Enzymes, Reagents And Kits Market Report Highlights
The global Cancer Stem Cells Market size is expected to reach USD 1.6 billion by 2025, according to a new report by Grand View Research, Inc., expanding at a CAGR of 9.98% during the forecast period. Although stem cell-based cancer treatment is facing regulatory and ethical challenges, the market is growing worldwide. With increasing awareness about these cells, there is steady growth in the R&D for the development of effective and novel treatment methods based on stem cells.
Furthermore, continuous rise has been observed in the number of research studies on cancer stem cells (CSCs) being published. These studies have helped healthcare professionals gain insights into CSCs biology and their signaling pathways. This is expected to create tremendous growth prospects for the market. Furthermore, improvements in experimental approaches, in particular, in vitro assay systems have enabled scientists to establish relationship between different cell types in a tumor and their microenvironment. This has led to development of a broad therapeutic portfolio for CSCs and their associated key pathways for restricting growth of the tumor and providing improved clinical outcome. Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/cancer-stem-cells-market Further key findings from the report suggest:
The global Medical Device Outsourcing Market size is expected to reach USD 231.2 billion by 2027, expanding at a CAGR of 10.4%, according to a new report by Grand View Research, Inc. The growing incidence of chronic diseases is one of the major factors contributing to market growth. Regulatory bodies are mainly focusing on the quality of the healthcare devices provided to the public. Hence this is encouraging various players in the market to offer various services like regulatory consulting. For example, the European Medical Device Regulation undertake special spontaneous inspection of outsourced products to test the quality as well as conformity with standards.
The importance of regulatory compliance is expected to boost the growth of consulting services such as remediation, compliance, and quality management systems (QMS), thereby contributing to market growth. Whereas, the budget scrutiny in developed countries, pricing pressure, and changes in reimbursement schemes are some of the major factors anticipated to increase the adoption of cost containment measures by the original equipment manufacturers (OEM). These factors are expected to boost medical device outsourcing to emerging countries like India and China. In addition, increasing difficulties in product engineering along with new entrants in the market are anticipated to shape the future of the market for medical device outsourcing. Whereas rising prevalence of chronic diseases is boosting the demand for medical devices. This, in turn, is helping the market to grow during the forecast period. Various companies are shifting their focus to research and development of new medical devices and are therefore outsourcing these activities to launch efficient medical devices in the market. Request a free sample copy or view report summary: Medical Device Outsourcing Market Report Medical Device Outsourcing Market Report Highlights
Healthcare Payer BPO Market Analysis by Xerox Corporation, Genpact Limited, Wipro Limited, Capgemini9/25/2020 Global Healthcare Payer BPO Market is expected to reach over USD 34.2 billion by 2022 according to a new report by Grand View Research Inc. Key drivers attributing to the growth are ObamaCare, shift to ICD-10 coding system, growing geriatric population, increasing disease burden and penetration of insurance coverage in emerging economies.
In 2013, as per estimates published by the America’s Health Insurance Plans (AHIP), which is the national trade association representing the health insurance industry, one-sixth of the U.S. economy or nearly USD 2.7 trillion is dedicated to healthcare spending and the number is expected to increase year on year. However, the healthcare system is not able to reap the benefits of such expenditure due to process inefficiencies and use of redundant systems. The estimated loss due to such inefficiencies is nearly 800 billion or approximately 20 to 30 percent of the overall expenditure. Increasing healthcare expenditure is a major concern for the U.S. and all the other major economies. In order to reduce the economic burden and provide universal access to healthcare, governments are encouraging outsourcing of payer services to onshore or offshore locations. The shift from ICD-9 coding system to ICD-10 coding has created huge work load for the payers to upgrade their systems, train their staff and has significantly increased the financial burden. The ICD-9 code system had 13,000 codes, where as the ICD-10 code system has nearly 68,000 codes. This shift from the legacy system to the latest system has significantly increased the need for medical coding, accounting, HR, and other technical professionals, thereby is expected to positively reinforce the healthcare payer BPO outsourcing market growth in the next seven years. Browse Details of Reports @ http://www.grandviewresearch.com/industry-analysis/healthcare-payer-bpo-market Further key findings from the study suggest:
The global Drug Discovery Informatics Market size is expected to reach USD 2.07 billion by 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 12.6% during the forecast period. Drug therapy is evolving in response to health care needs of the population. The most recent trend is to develop drugs for treatment of chronic diseases, especially those affecting the older population.
Cardiovascular Diseases (CVDs), stroke, and cancer are the most prevalent health issues and also the most common conditions causing death. Moreover, treatment expenses and costs pertaining to these diseases are very high, which triggers the demand for effective novel molecules. In the U.S. alone, revenue generated through CVD treatments was over USD 444 billion in 2010, and it has been estimated to claim more lives each year than the remaining causes of death combined. Clinical decision support tools, which include online database for assistance in enhancement of clinical decisions, are timely updated and that significantly impacts market growth. Moreover, the World Health Organization's Consultative Expert Working Group for Research and Development is also involved in evaluation and development of open source drug discovery platforms. Introduction of open drug discovery tool kit (ODDT), which serves as a tool for computer-aided drug discovery by implementing machine learning scoring functions (RF-Score and NN-Score), is anticipated to work in favor of the market. Request a sample copy or view summary of this report@ https://www.grandviewresearch.com/industry-analysis/drug-discovery-informatics-market Further key findings from the report suggest:
Global Point Of Care Lipid Test Market size is expected to reach USD 280.02 million by 2022 according to a new report by Grand View Research Inc. Growing geriatric population base, increasing global prevalence of cardiovascular diseases, and rising healthcare awareness due to patient education are the driving forces for the PoC Lipid Test industry growth during the forecast period.
Furthermore, continuous efforts by the government to reduce hospital stays and curb healthcare expenditure, establishments attempting to provide effective and rapid diagnostic results, and improvement in technology with the provision of cheap and high-quality medical solutions aimed at achieving lab automation are some factors contributing to the growth of the PoC Lipid Test market. Request a sample copy or view summary of this report @ http://www.grandviewresearch.com/industry-analysis/point-of-care-poc-lipid-test-market Further key findings from the study suggest:
Europe Real Time Polymerase Chain Reaction (Qpcr) Market is expected to reach over USD 395.8 million by 2022, according to a new report by Grand View Research Inc. Technological advancements on the grounds of accuracy, portability, and cost-effectiveness are expected to serve this market as high-impact rendering drivers over the forecast period. For instance, Applied Biosystems has QuantStudio Dx series for rapid and affordable diagnosis of molecular abnormalities at early stage of diseases development.
Increasing amount of R&D expenditure by the major players and development of novel assay kits are expected to provide potential growth platform for adoption of qPCR instruments for diagnostic use. Growing prevalence of cancer and other chronic diseases is anticipated to be the key driver for the industry growth. Moreover, growing geriatric population base in EU-28 countries is expected to increase age-related conditions such as diabetes and cardiovascular disorders. Furthermore, major pharmaceutical companies are entering into collaborations with diagnostic instrument development companies through mergers and acquisitions or co-product development activities. For instance, in 2011, Life Technologies signed an agreement with GSK Biologicals to develop a companion diagnostic test. Life Technology will develop a qPCR based diagnostic assay for GSK’s MEGA-A3 cancer immunotherapy. Emerging opportunities for both companies for development of products pertaining to early detection of diseases such as cancer and infectious diseases are estimated to enhance such collaborative activities over the forecast period. Request a sample copy or view summary of this report@ http://www.grandviewresearch.com/industry-analysis/europe-real-time-polymerase-chain-reaction-market Further key findings from the study suggest:
Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market is expected to reach USD 566.4 million by 2020. Rising R&D leading to the introduction of new drugs for IVIG and TPO-RA classes is expected to propel growth over the forecast period. In addition, government regulation such as the Orphan Drug Act in the United States with an aim to encourage new product development is projected to fuel growth.
The industry is characterized by rising demand for combination therapies as they exhibit higher efficiency as compared to other treatments. Moreover, they are cost efficient and help curb side effects associated with individual therapeutic classes. Some of the major combination therapies are dexamethasone and rituximab, dexamethasone and TPO-RA, IVIG and corticosteroids. Splenectomy, the procedure to remove spleen is aimed at reducing the amount of anti-platelet antibodies, is expected to fuel demand. The global market for corticosteroid is valued at over USD 125.0 million in 2013. Corticosteroids are regularly used in idiopathic thrombocytopenic purpura treatment. Since corticosteroid are considered to be the first line of therapy for patients suffering from ITP, the usage rates of corticosteroid are very high. Browse Details of Report @ http://www.grandviewresearch.com/industry-analysis/idiopathic-thrombocytopenic-purpura-itp-therapeutics TPO-RA is likely to witness substantial growth, growing at a CAGR of over 9.0% from 2014 to 2020 owing to high response rates exhibited by patients administered with Eltrombopag and Romiplostim. Moreover, demand for TPO-RA is expected to increase due to the commercialization of Avatrombopag in 2015. In addition, the ability of TPO-RA to cater to splenectomized patients witnessing relapses is expected fuel demand over the next six years. North America accounted for a majority share in 2013 due to rising occurrence of diseases coupled with the presence of high treatment rates, favorable government initiatives, and funding programs. North America had a share of over 40% of the global ITP market by revenue in 2013 and is expected to witness high demand over the forecast period. Europe accounted for the second largest market share in 2013. This trend is projected to continue over the forecast period due to high usage rates of products along with government initiatives granting of special status to orphan drugs factors. Asia Pacific is expected to experience substantial growth over the next six years, owing to the presence of favorable government initiatives, and sophisticated healthcare infrastructure in Australia and Japan. In addition, the presence of vast untapped opportunities in emerging markets such as China and India is expected to propel growth. Some of the major players in the industry are and GlaxoSmithKline Plc., Hoffman-L Roche, Amgen Inc and Grifols Biologicals Inc. The companies make significant R&D investments aimed at new product development by taking advantage of incentives offered under the pertinent government regulations. The global Cord Blood Banking Services Market is expected to reach over USD 82.3 billion by 2025, growing at an estimated CAGR of around 11.9% from 2017 to 2025, according to a new study by Grand View Research, Inc. Key drivers of the market include increasing application of stem cell therapies in disease treatment, and rising prevalence of life threatening genetic disorders.
Moreover, increasing spending capacity is fueling the demand for advanced healthcare facilities including disease prevention and treatment. As a result, parents are increasingly demanding CBB services to ensure safety of their child’s future. Furthermore, private players are practicing marketing activities which are creating awareness about the availability of the CBB services and their benefits. In addition, governments worldwide are promoting public CBB to develop ethnically diverse cord blood repository which would increase the chances of finding suitable human leukocyte antigen (HLA) match for the patients. As a result, availability of the ethnically rich CB repository coupled with anticipated rise in the stem cell therapies and bone marrow transplants, is expected to spur the CBB services during the forecast period. Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/cord-blood-banking-services-market Further Key Findings From the Report Suggest:
|
Archives
October 2023
|